587 related articles for article (PubMed ID: 20598860)
1. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
2. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).
Mendes RE; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):93-7. PubMed ID: 21851873
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
Saravolatz LD; Pawlak J; Johnson LB
J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
[TBL] [Abstract][Full Text] [Related]
4. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
6. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
Farrell DJ; Krause KM; Benton BM
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):275-9. PubMed ID: 21353951
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
10. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).
Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN
J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
[TBL] [Abstract][Full Text] [Related]
15. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
17. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
Mendes RE; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
[TBL] [Abstract][Full Text] [Related]
18. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
Hope R; Chaudhry A; Adkin R; Livermore DM
Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
[TBL] [Abstract][Full Text] [Related]
20. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
Dowzicky MJ; Chmelařová E
Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
